Suppr超能文献

中药复方开心散的急性和亚慢性经口毒性评价。

Acute and subchronic oral toxicity assessment of the herbal formula Kai-Xin-San.

机构信息

Department of Clinical Pharmacology, General Hospital of PLA, Fuxing Road, 28, Beijing 100853, China.

出版信息

J Ethnopharmacol. 2011 Nov 18;138(2):351-7. doi: 10.1016/j.jep.2011.08.033. Epub 2011 Aug 22.

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE

Kai-Xin-San (KXS) is a famous traditional Chinese medicine (TCM) formula. It has been used in the treatment of diseases including neurasthenia, Alzheimer's disease and neurosis.

AIM OF THE STUDY

To provide information on the potential toxicity of KXS, we evaluated the acute and subchronic toxicity in rodents.

MATERIALS AND METHODS

In acute study, a single administration of KXS was given orally to mice at doses ranging from 19.67 to 60.04 g/kg. In the sub-chronic oral toxicity study, KXS was administered to rats at 0, 1, 3 and 9 g/kg for 13 weeks. Moreover, 30 days of post treatment (withdrawal study) was conducted. Mortalities, clinical signs, body weight changes, food and water consumption, haematological and biochemical parameters, gross findings and organ weights were monitored during the study period.

RESULTS

In the sub-chronic study in rats, daily oral administration of KXS at the dose of 9 g/kg/day result in significant increase in WBC, lymphocyte, alkaline phosphatase, blood sugar and significant decrease in bodyweight, serum Cre, CK and CHO at the last week of treatment. Recovery except for the body weight was observed after 30 days of post treatment.

CONCLUSIONS

KXS is relatively safe for oral medication. The LD(50) of KXS was over 32.59 g/kg for mice. The no-observed-adverse-effect-level (NOAEL) was considered to be 19.67 g/kg/day for rats.

摘要

民族药理学相关性

开心散(KXS)是一种著名的中药(TCM)配方。它已被用于治疗包括神经衰弱、老年痴呆症和神经症在内的疾病。

研究目的

为了提供 KXS 潜在毒性的信息,我们评估了啮齿动物的急性和亚慢性毒性。

材料和方法

在急性研究中,将 KXS 单次口服给予小鼠,剂量范围为 19.67 至 60.04 g/kg。在亚慢性口服毒性研究中,将 KXS 以 0、1、3 和 9 g/kg 的剂量给予大鼠,为期 13 周。此外,进行了 30 天的治疗后(停药研究)。在研究期间监测死亡率、临床症状、体重变化、食物和水的消耗、血液学和生化参数、大体发现和器官重量。

结果

在大鼠的亚慢性研究中,每日口服 KXS 剂量为 9 g/kg/天时,在治疗的最后一周导致白细胞、淋巴细胞、碱性磷酸酶、血糖显著增加,体重、血清 Cre、CK 和 CHO 显著下降。在 30 天的治疗后观察到除体重外的恢复。

结论

KXS 口服给药相对安全。KXS 对小鼠的 LD(50)超过 32.59 g/kg。大鼠的无观察不良效应水平(NOAEL)被认为是 19.67 g/kg/天。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验